China Pharma Holdings (CPHI) Other Working Capital Changes (2019 - 2026)
China Pharma Holdings' (CPHI) quarterly Other Working Capital Changes came in at $1.5 million in Q1 2020, up 12025.36% on a YoY basis from N/an in Q2 2019, and up 714748.78% quarter-over-quarter from -$205.0 in Q4 2019.
Analysis
China Pharma Holdings (CPHI) Other Working Capital Changes (2019 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has reported Other Working Capital Changes for 11 consecutive years, with $1.5 million the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Other Working Capital Changes rose 12025.36% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2020 stood at $1.5 million (up 2619.64% YoY), and the FY2019 full-year result was -$12875.0, up 48.76% from the prior year.
- Other Working Capital Changes grew to $1.5 million in Q1 2020 per CPHI's latest filing, from -$205.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $452021.0 in Q4 2022 and bottomed at -$392021.0 in Q1 2023.
- Historically, Other Working Capital Changes has averaged -$3547.0 across 5 years, with a median of -$42449.5 in 2025.
- The sharpest annual moves came in 2018 and 2020: Other Working Capital Changes slumped 1145.57% in 2018, then soared 12025.36% in 2020.
- Over 5 years, Other Working Capital Changes stood at -$166976.0 in 2016, then soared by 94.62% to -$8976.0 in 2017, then plunged by 1145.57% to -$111802.0 in 2018, then surged by 99.82% to -$205.0 in 2019, then jumped by 714748.78% to $1.5 million in 2020.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.5 million, -$205.0, and -$44218.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89,409.00 |
| Jun 30, 2026 | 89,409.00 |
| Mar 31, 2026 | -51,376.00 |
| Mar 31, 2026 | -51,376.00 |
| Jun 30, 2025 | -36,880.00 |
| Jun 30, 2025 | -36,880.00 |
| Mar 31, 2025 | -48,019.00 |
| Mar 31, 2025 | -48,019.00 |
| Dec 31, 2024 | 139,322.00 |
| Dec 31, 2024 | 139,322.00 |
| Sep 30, 2024 | -76,748.00 |
| Sep 30, 2024 | -76,748.00 |
| Jun 30, 2024 | -10,840.00 |
| Jun 30, 2024 | -10,840.00 |
| Mar 31, 2024 | 21,982.00 |
| Mar 31, 2024 | 21,982.00 |
| Dec 31, 2023 | -82,849.00 |
| Dec 31, 2023 | -82,849.00 |
| Sep 30, 2023 | 118,587.00 |
| Sep 30, 2023 | 118,587.00 |